Description
Interleukin 13 receptor alpha 2, also known as IL13RA2 and CD213A2, binds IL13 with high affinity, but lacks cytoplasmic domain, and does not appear to function as a signal mediator. IL13RA2 serves as a dominant negative inhibitor or a decoy receptor for IL-13. IL-13Ralpha2 is a promising target for ovarian cancer therapy, and the soluble form of IL-13R may be a possible surrogate marker for disease monitoring. IL13RA2 signaling during prolonged inflammation is also an important therapeutic target for the prevention of TGF-beta(1)-mediated fibrosis